Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension

J Cardiovasc Pharmacol. 2005 Dec;46(6):735-9. doi: 10.1097/01.fjc.0000185783.00391.60.

Abstract

Chronic inflammation is common in hypertension and acts as an independent determinant of arterial blood pressure. Hypertensive patients are reported to have high circulating levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and C-reactive protein (CRP). Recently, angiotensin II receptor blockers (ARBs) have been shown to possess benefits in addition to their ability to lower blood pressure, including anti-inflammatory and antioxidative properties within the vasculature. We evaluated the effects of the angiotensin II receptor blocker, valsartan, on these inflammatory cytokines. Thirty-nine patients with essential hypertension participated. These subjects received valsartan, 40 to 80 mg/day. Serum TNF-alpha, IL-6, CRP, and serum amyloid A (SAA) were measured before and after 3 months of treatment with valsartan. Valsartan significantly decreased systolic and diastolic blood pressure (160 +/- 16/92 +/- 11 mm Hg to 147 +/- 21/84 +/- 11 mm Hg, P = 0.001/P = 0.001, respectively). Serum TNF-alpha (9.1 +/- 8.6 pg/mL to 6.1 +/- 1.0 pg/mL, P = 0.006) and IL-6 (9.3 +/- 1.7 pg/mL to 8.9 +/- 1.4 pg/mL, P = 0.005) were significantly reduced after treatment with valsartan. However, C-reactive protein and serum amyloid A did not change. The angiotensin II receptor blocker, valsartan, may inhibit the development of atherosclerosis by lowering serum pro-inflammatory cytokines.

MeSH terms

  • Adult
  • Aged
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Blood Pressure / drug effects
  • C-Reactive Protein / analysis
  • Cytokines / blood*
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / immunology
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Serum Amyloid A Protein / analysis
  • Tetrazoles / pharmacology*
  • Tetrazoles / therapeutic use
  • Tumor Necrosis Factor-alpha / analysis
  • Valine / analogs & derivatives*
  • Valine / pharmacology
  • Valine / therapeutic use
  • Valsartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Cytokines
  • Interleukin-6
  • Serum Amyloid A Protein
  • Tetrazoles
  • Tumor Necrosis Factor-alpha
  • Valsartan
  • C-Reactive Protein
  • Valine